Physician profile
Arnold Kaplin
NPI 1497864748
$6,492.92
in general payments reported to CMS, 2019-2025
13 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $268 · 2021: $110 · 2022: $892 · 2023: $1,027 · 2024: $1,528 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,837.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,106.60 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,043.89 | 2022-2025 | |
| Allergan, INC. | $756.25 | 2019-2020 | |
| Axsome Therapeutics, INC. | $616.90 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $615.06 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $605.28 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $469.35 | 2024-2025 | Fanapt |
| Alkermes, INC. | $354.84 | 2022-2024 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $334.66 | 2022-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $299.09 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $216.44 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.83 | 2019-2021 | |
| Tris Pharma INC | $23.73 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Kaplin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.